M. Iborra Colomino-rekin lankidetzan egindako argitalpenak (17)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2022

  1. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 4, pp. 614-624

  2. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

    Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641

  5. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2020

  1. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

    Scientific Reports, Vol. 10, Núm. 1

  2. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

    Current Medical Research and Opinion, Vol. 35, Núm. 7, pp. 1297-1304

  3. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study

    Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 8, pp. 807-813

  4. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  5. Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: Results from the PRACTICROHN study

    Gastroenterology Report, Vol. 7, Núm. 6, pp. 411-418

  6. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288

2018

  1. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851

2017

  1. Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study

    Inflammatory Bowel Diseases, Vol. 23, Núm. 10, pp. 1840-1846

2016

  1. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41